KEY TAKEAWAYS
- The study aimed to investigate the impact of age on metastatic patterns and survival outcomes in dnMBC.
- Researchers noticed age-related variations in metastatic patterns and survival outcomes among patients with dnMBC.
Is de novo metastatic breast cancer (dnMBC) the same disease in the elderly as in younger BC remains unclear.
Ke Liu and the team aimed to determine the metastatic patterns and survival outcomes in dnMBC according to age groups.
They performed an inclusive analysis using data from the Surveillance Epidemiology and End Results program. Statistical analyses involved Chi-square tests, multivariate logistic regression analyses, and multivariate Cox regression models to investigate associations between age, metastatic patterns, and survival outcomes in patients with dnMBC.
About 17,719 patients were included in the analysis. Patients were distributed across age groups as follows: <35 years (3.6%, n=638), 35-49 years (18.6%, n=3290), 50-64 years (38.0%, n=6725), and ≥65 years (39.9%, n=7066). Older patients exhibited a significantly higher incidence of lung metastasis and a lower incidence of liver metastasis. Lung metastasis rates were 19.1%, 25.6%, 30.9%, and 35.7% in age groups <35, 35-49, 50-64, and ≥65 years, respectively, while liver metastasis rates were 37.6%, 29.5%, 26.3%, and 19.2%, respectively.
Age emerged as an independent prognostic factor for both breast cancer-specific survival (BCSS) and overall survival (OS). Patients aged 50-64 and ≥65 years demonstrated significantly inferior BCSS (P<0.001) and OS (P<0.001) compared to those <35 years. Conversely, outcomes between patients aged 35-49 and <35 years were similar.
The study concluded that age groups exert varying impacts on metastatic patterns in dnMBC, with younger patients experiencing more favorable survival outcomes compared to older counterparts.
The study received no funds.
Source: https://pubmed.ncbi.nlm.nih.gov/38752173/
Liu K, Huang AL, Chen XQ, et al. (2024). “Patterns of distant metastasis and survival outcomes in de novo metastatic breast cancer according to age groups.” Front Endocrinol (Lausanne). 2024 May 1;15:1385756. doi: 10.3389/fendo.2024.1385756. PMID: 38752173; PMCID: PMC11094241.
